ArTS Archivio della ricerca di Trieste

SPALLUTO, GIAMPIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.260
EU - Europa 4.593
AS - Asia 1.204
AF - Africa 35
SA - Sud America 34
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 8
Totale 15.152
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.227
SE - Svezia 1.188
IT - Italia 938
UA - Ucraina 692
CN - Cina 405
PL - Polonia 396
HK - Hong Kong 340
TR - Turchia 288
DE - Germania 245
FI - Finlandia 230
FR - Francia 217
GB - Regno Unito 187
IE - Irlanda 154
BG - Bulgaria 137
CH - Svizzera 54
IN - India 41
BE - Belgio 39
RU - Federazione Russa 39
SG - Singapore 36
CA - Canada 32
BR - Brasile 25
NL - Olanda 21
ES - Italia 18
EU - Europa 17
MY - Malesia 16
ID - Indonesia 14
AT - Austria 13
JP - Giappone 12
SN - Senegal 10
VN - Vietnam 10
EG - Egitto 8
BD - Bangladesh 7
PK - Pakistan 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
IL - Israele 6
IR - Iran 6
KR - Corea 6
AU - Australia 5
CL - Cile 5
CO - Colombia 4
DK - Danimarca 3
HU - Ungheria 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BY - Bielorussia 2
IQ - Iraq 2
KZ - Kazakistan 2
MA - Marocco 2
PS - Palestinian Territory 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
ET - Etiopia 1
HR - Croazia 1
JO - Giordania 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
SC - Seychelles 1
TW - Taiwan 1
TZ - Tanzania 1
Totale 15.152
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.134
Fairfield 1.131
Houston 998
Ann Arbor 965
Chandler 656
Jacksonville 627
Wilmington 570
Ashburn 557
Seattle 469
Warsaw 391
Cambridge 376
Hong Kong 337
Izmir 271
Princeton 255
Trieste 236
Beijing 142
Dublin 138
Sofia 137
Boardman 111
Milan 79
San Diego 68
Buffalo 65
Menlo Park 58
Mestre 58
Verona 48
Bern 47
Columbus 47
Munich 45
Bremen 41
West Jordan 41
Dearborn 36
Brussels 30
Guangzhou 30
Falls Church 27
Sacile 27
Shanghai 25
Des Moines 23
Redwood City 22
Singapore 21
Chicago 20
Düsseldorf 20
Phoenix 20
São Paulo 20
Toronto 20
Rome 19
Helsinki 16
Norwalk 16
New York 15
Vienna 13
Codroipo 12
Nanchang 12
Nanjing 12
Pittsburgh 12
Southend 12
Torre Del Greco 12
Frankfurt am Main 11
Padova 11
Philadelphia 11
Udine 11
Dakar 10
Ferrara 10
Kocaeli 10
Scottsdale 10
Council Bluffs 9
Fremont 9
Jinan 9
London 9
Tulsa 9
Auburn Hills 8
Cividale del Friuli 8
Dong Ket 8
Jakarta 8
Madrid 8
Nuremberg 8
San Jose 8
Cairo 7
Dopākul 7
Hefei 7
Istanbul 7
Lachine 7
Moscow 7
Pune 7
Suffern 7
Tappahannock 7
Abidjan 6
Brno 6
Detroit 6
Hangzhou 6
Kuala Lumpur 6
Kunming 6
Vitoria-Gasteiz 6
Zurich 6
Antwerpen 5
Bologna 5
Boydton 5
Camerino 5
Citta 5
Dallas 5
Delhi 5
Grafing 5
Totale 10.926
Salva come PNG Salva come JPEG
Nome #
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment 359
The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives 348
1,2,4-Triazolo[1,5-a]-1,3,5-triazine nucleus: a possible template for adenosine receptor subtypes. 292
null 245
[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype 225
null 217
null 214
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 209
null 197
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition 180
Hemolytic Effects of Water-Soluble Fullerene Derivatives 179
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5- c ]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study 173
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 166
Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δinhibitors 166
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 165
CC-1065 and Duocarmycins: Recent Developments 164
Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors. 161
null 161
ANTI-HIV PROPERTIES OF CATIONIC FULLERENE DERIVATIVES 159
. 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 158
null 154
null 153
Chemical probes for the adenosine receptors 150
Carbon nanotube substrates boost neuronal electrical signaling 146
Synthesis of a Hybrid Fullerene-Trimethoxyindole-Oligonucleotide Conjugate 145
Synthesis, Biological properties and molecular modeling investigation of the first potent, selective and water soluble human A3 adenosine receptor antagonist 145
Synthesis and anti-HIV properties of new water-soluble bis-functionalized [60]fullerene derivatives 143
Design, Synthesis and Biological Properties of Fulleropyrrolidine Derivatives as Potential DNA Photo-Probes 143
null 140
Anti-inflammatory and anti-oxidant activity of a new class of phenyl-pyrazolone derivatives. 138
Advances in Computational Techniques to Study GPCR-Ligand Recognition 135
Synthesis, biological activity and molecular modeling investigation of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A3 adenosine receptor antagonists 134
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 133
1,2,4]Triazolo[1,5-c]pyrimidines as New Potent Human A3 Adenosine Receptor Antagonists. 132
DNA-Photocleavage Agents 131
PYRAZOLO TRIAZOLO PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS: EFFECT OF THE N-5 BOND TYPE ON THE AFFINITY AND SELECTIVITY AT THE FOUR ADENOSINE RECEPTOR SUBTYPES 129
Chapter 1: A3 adenosine receptor ligands in the treatment of inflammation and cancer 129
Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: A possible template for adenosine receptor subtypes? 128
A new Multi-charged C60 Derivative: Synthesis and Biological Properties 127
Response surface analysis as alternative 3D-QSAR tool: human A3 adenosine receptor antagonists as a key study. 126
Ligand based-homology modeling as attractive tool to inspect GPCR structural plasticity 126
Design, synthesis and evaluation of new indolylpyrimidylpiperazines for gastrointestinal cancer therapy 126
Synthesis and biological evaluation of a new series of 1,2,4-Triazolo(1,5-a)-1,3,5-triazines as human A2A adenosine receptor antagonists with improved water solubility 126
Synthesis and Biological Studies of a New Series of 5-Heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists. Influence of the Heteroaryl Substituent on Binding Affinity and Molecular Modeling Investigations 123
Novel Versatile Fullerene Synthons 123
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 123
New 2,6,9 tri-substituted adenines as adenosine receptor antagonists: a preliminary SAR profile. 122
Rational Design, synthesis, and evaluation of a key analogues of CC-1065 and the duocarmycins. 122
Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors 122
Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies 122
The A3 adenosine receptor as multifaceted therapeutic Target: pharmacology, medicinal Chemistry, and In silico approaches 121
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View? 120
null 116
N8-Isopentyl and N8-Phenylethyl Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives as Adenosine Receptor Antagonists 115
null 112
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A(3) and A(2B) adenosine receptor subtypes: A molecular modeling investigation 111
Potent and selective A2A adenosine receptor antagonists: Recent Improvements 110
Biological Applications of Fullerene Derivatives: A Brief Overview 110
7-Substituted-5-amino-2-(2-furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility 110
A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4- d ]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists 108
Fullerene derivatives: an actractive tool for biological application 107
G protein-coupled receptors as challenging druggable targets: insights from in silico studies 107
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example 106
Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3 Adenosine Receptor Antagonists: Influence of the Chain at the N8 pyrazole Nitrogen. 105
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. 105
Synthesis and Molecular Modeling Studies of Fullerene-Trimethoxyindole-Oligonucleotide Conjugates as Possible Probes for Studying Photochemical Reactions in DNA Triple Helices 104
Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells 104
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptor antagonists: new insights into structure affinity relathionship and receptor antagonist recognition. 104
Mixed-reversible and covalent kinase inhibition as a possible new strategy to treat neuro-inflammatory/degenerative diseases 103
Conjugable A3 adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes 102
Fluorescent ligands for adenosine receptors 101
null 99
Exploring the Directionality of 5-Substitutions in a New Series of 5-Alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptor Antagonists. 98
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 98
Progress in the pursuit of therapeutic adenosine receptor antagonists 97
Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. 97
Structural investigations on a novel class of 1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptor antagonists. 97
null 97
Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography. 96
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling 96
Fluorosulfonyl- and Bis-(b-Chloroethyl)amino-Phenylamino Functionalized Pyrazolo[4,3-e]1,2,4-Triazolo[1,5-c]Pyrimidine Derivatives: Irreversible Antagonists at the Human A3 Adenosine Receptor and Molecular Modeling Studies 95
Oligonucleotides and Oligonucleotide Conjugates: A New Approach for Cancer Treatment 94
Autocorrelation of molecular electrostatic potential surface properties combined with the partial least squares analysis as alternative attractive tool to generate ligand-based 3D-QSARs 94
Novel fluorescent antagonist as a molecular probe in A3 adenosine receptor binding assays using flow cytometry. 93
null 93
The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy 92
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems 92
Anticonvulsivanti 91
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists 91
A2B Adenosine Receptor Antagonists: Recent Developments 90
Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update 89
A3 Adenosine receptor antagonistsdelay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro 89
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonists as a potential anti-Parkinson multitarget approach. 89
null 89
Fullerene Derivatives as Potential DNA Photoprobes 88
Medicinal chemistry of A2A adenosine receptor antagonists 88
Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2Aligand binding kinetics 84
Tecniques: recent developments in computer aided engineering of GPCR ligands using the human A3 adenosine receptor as an example. 83
A facile and versatile route to the synthesis of fused 2-pyridones: Useful intermediates for policyclic systems 77
[1,2,4]Triazolo[1,5-c]pyrimidine Nucleus as Adenosine Receptor Antagonists: Shift in Selectivity from A2A to A3 Adenosine Receptors. 76
Totale 13.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.756
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019898 0 0 0 0 0 0 0 0 0 0 664 234
2019/20203.165 147 169 192 546 275 439 293 356 270 191 206 81
2020/20212.270 235 109 216 320 186 245 157 178 110 208 97 209
2021/20221.757 121 147 76 387 23 101 66 59 175 215 87 300
2022/20232.229 201 264 161 300 222 433 6 200 285 31 91 35
2023/20241.255 109 109 82 126 112 94 209 333 5 72 4 0
Totale 15.636